[Cerebrolysin as an early add-on to reperfusion therapy: heterogeneous treatment effect analysis in ischemic stroke patients with varying risk of hemorrhagic transformation].
Kalinin MN, Khasanova DR · 2024 · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova; 2024
Study findings
Reported treatment associations varied with baseline hemorrhagic-transformation risk; the low-risk subgroup showed neutral effects.
- Population and setting
- CEREHETIS post hoc analysis: 238 patients
- Evidence type
- Human comparative study
- Preparation
- See the original report; formulation details require verification.
- Source language
- rus
- Title source
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
Study limitations
- Post hoc subgroup analysis is exploratory.
- Overlaps the CEREHETIS trial and potentially its other language/version reports.
- Full methods and risk of bias have not been independently assessed.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Related-report group: CEREHETIS. Reports in this group are not assumed to be independent trials.
Source access and review scope
Indexed record and available abstract checked; full text not reviewed.
Recorded source-check date: 2026-10-07. This date does not imply a completed systematic review.
Citation and original source
Original source: Kalinin MN, Khasanova DR. [Cerebrolysin as an early add-on to reperfusion therapy: heterogeneous treatment effect analysis in ischemic stroke patients with varying risk of hemorrhagic transformation]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova; 2024 2024.
Molekul research summary: https://molekul.io/research/cbl-update-38512096. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry